The CD19 protein forms a complex with CD21, CD81, and CD225 in the membrane of mature B cells. Together with the B-cell antigen receptor, this complex signals the B cell to decrease its threshold for activation by the antigen.
P rimary antibody deficiencies, which are associated mainly with susceptibility to bacterial infections, can be caused by mutations in genes involved in B-cell differentiation. 1 Such genetic defects block the differentiation of immature B cells in bone marrow, thereby causing both a deficiency of mature B cells in the peripheral circulation and agammaglobulinemia. [2] [3] [4] [5] [6] [7] [8] In disorders involving defects in the maturation process of antigen-responsive B cells, by contrast, there are mature B cells in blood and a deficiency of some, but not all, immunoglobulin classes (dysgammaglobulinemia) or hypogammaglobulinemia. These disorders fall into two categories. The hyper-IgM syndromes are those in which a genetic defect impairs immunoglobulinclass switching (e.g., IgM to IgG) or impairs somatic mutation of immunoglobulin genes (a molecular sign of a response to an antigen), or both. [9] [10] [11] [12] The second category is common variable immunodeficiency, a syndrome involving hypogammaglobulinemia, recurrent bacterial infections, and a lack of antibody production in response to vaccination. Genetic defects have been found in some patients with common variable immunodeficiency, 13, 14 but no genetic abnormality is evident in more than 80 percent of such patients.
During B-cell differentiation in the bone marrow, the surface molecule CD19 appears early and remains on the B cell until it differentiates into a plasma cell. Four proteins on the surface of mature B cells -CD19, CD21, CD81, and CD225 -form the CD19 complex, which signals in conjunction with the B-cell antigen receptor, thereby decreasing the threshold for receptor-dependent signaling. 15 We describe four patients, from two unrelated families, who had hypogammaglobulinemia and defective CD19. These patients had normal levels of B cells in blood but had undetectable or very low levels of surface CD19, owing to a homozygous mutation in the CD19 gene. The deficiency of antibody in these patients resulted from a subnormal response to antigen by mature B cells.
C a se R eports
Patient 1, a girl of Turkish descent and the second child of consanguineous parents (second cousins), was referred to the Selçuk University Hospital in Konya, Turkey, at 10 years of age with a sevenmonth history of intermittent hematuria. She also had a history of recurrent bronchiolitis and bronchopneumonia starting at one year of age and meningitis starting at eight years of age. On physical examination, her heart rate was 118 beats per minute and auscultation of the lung revealed rhonchi and wheezing. The differential blood count was normal, but urinalysis showed microscopic hematuria without proteinuria. The complement levels were normal, tests for antinuclear antibodies were negative, the erythrocyte sedimentation rate was 41 mm per hour, and the level of C-reactive protein was 93 mg per deciliter. The dermal response to purified protein derivative after two vaccinations with bacille Calmette-Guérin was 12 mm. Renal ultrasonography showed no abnormalities; a renal biopsy revealed proliferation of mesangial cells, interstitial edema, and an apparently normal basement membrane of the glomerulus. She was given a diagnosis of postinfectious glomerulonephritis and was also found to have hypogammaglobulinemia (Table 1) .
Patients 2, 3, and 4 were siblings, children of unrelated parents of Colombian descent, and were examined at the Primary Immunodeficiencies Clinic of the University of Antioquia in Medellín, Colombia, at 35, 33, and 49 years of age, respectively. All three had had otitis media, sinusitis, and pharyngitis during childhood. In addition, Patient 2 (the index patient) had had four bouts of pneumonia between the ages of 18 and 35 years; more recently, he had received diagnoses of bacterial conjunctivitis and chronic gastritis (Heliobacter pylori infection). He was given a diagnosis of hypogammaglobulinemia due to common variable immunodeficiency (Table 1) . His two sisters also had hypogammaglobulinemia (Table 1) and histories of recurrent upper respiratory tract infections. Patient 3 first had pneumonia at 20 years of age, herpes zoster at 30 years of age, and more recently, recurrent bacterial conjunctivitis with dacryocystitis and diarrhea. Patient 4 had had pneumonia at eight years of age, recurrent skin abscesses and more bouts of pneumonia during childhood, and chronic diarrhea, bronchitis, and recurrent bacterial conjunctivitis during adulthood. These three patients had had surgery for chronic sinusitis.
Intravenous immune globulin therapy was initiated in all four patients soon after the diagnosis of hypogammaglobulinemia. All patients are now clinically well, with no signs of lymphoproliferation, cancer, or autoimmunity. The other siblings of both families have normal serum immunoglobulin levels and no symptoms of immunodeficiency. However, one sibling of Patients 2, 3, and 4 was given a diagnosis of systemic lupus erythematosus at 13 years of age, according to the criteria of the American Rheumatism Association. 17
Me thods
Diagnostic workups of blood, biopsy of bone marrow, cervical lymph node, and tonsil, and rabies vaccination were carried out in patients and family members after they provided oral informed consent and according to the guidelines of the local medical ethics committees in Turkey, Colombia, and the Netherlands. Controls provided written consent.
Amplification and Sequence Analysis of the CD19 Gene
The CD19 gene on chromosome 16 (16p11.2) spans 7.5 kb of genomic DNA and codes for a protein of 556 amino acids, including the signal peptide. 18 DNA was isolated from granulocytes that had been isolated with the use of Ficoll gradient centrifugation. All 15 exons were amplified by the polymerase chain reaction (PCR) (the primer sequences are listed in Part A of the Supplementary Appendix, available with the full text of this article at www.nejm.org) and were sequenced on an ABI Prism 377 fluorescent sequencer (Applied Biosystems).
Total complementary DNA (cDNA) was prepared from messenger RNA (mRNA) that had been isolated from the patients' mononuclear cells, as described previously. 19 Fragments of CD19 cDNA were amplified and sequenced to verify the mutations found in the genomic DNA.
CD19 Transcripts
Levels of the CD19 transcript in blood B cells were quantified from reverse-transcribed mRNA from patients' blood mononuclear cells with the use of TaqMan real-time quantitative PCR with newly designed primers and a FAM-TAMRA-labeled fluorogenic probe (sequences are given in Part B of the Supplementary Appendix). The transcript lev- 
Analysis of somatic hypermutation
Hypermutation of immunoglobulin genes was studied in the V H 3-C α , V H 4-C α , V H 3-C γ , and V H 4-C γ fragments, which were amplified from the cDNA and cloned into a pGEM-T easy vector (Promega). Twenty-one clones of Patient 1, 44 clones of Patient 2, 39 clones of Patient 3, and 39 clones of Patient 4 were sequenced. The International Im-MunoGeneTics information system (http://imgt. cines.fr/) was used to identify the V, D, and J segments and somatic mutations. 21 The ratio of replacement and silent mutations was determined for the framework regions and the complementarity-determining regions, and the distribution of replacement mutations in the framework regions was analyzed according to the binomial distribution model of Chang and Casali. 22 
Flow Cytometry
Flow-cytometric immunophenotyping of blood samples from four patients, nine relatives (including eight carriers), and eight controls was performed to evaluate markers and subgroups of B cells. We also analyzed bone marrow samples from Patient 1 and from five controls, as previously described. 23 Antibodies against CD21 (LB21), CD81 (JS-81), and CD225 (Leu13) were used to analyze the CD19 complex further. 15, 24 Western Blotting B cells in blood were sorted from mononuclear cells with the use of the magnetic affinity cellsorting B-cell purification kit (Miltenyi Biotec). Lysates of B cells (2×10 6 ) were separated by sodium dodecyl sulfate-polyacrylamide-gel electrophoresis and immunoblotted with the use of a polyclonal rabbit antiserum against the intracellular portion of human CD19. 25
Histology and Immunohistochemistry
The biopsy specimen of a cervical lymph node from Patient 1 and the tonsil-biopsy specimen from Patient 2 were fixed in formalin, embedded in paraffin, and stained with hematoxylin and eosin. Immunohistochemistry was performed according to standard procedures involving monoclonal antibodies against CD20 (L26), CD21 (1F8), CD79a (JCB117), BCL-2 (124), BCL-6 (PG-B6p), and Ki67 (MIB-1), all obtained from DakoCytomation.
B-Cell Activation
Blood mononuclear cells were incubated with 6 μg of indo-1 per milliliter of cell suspension (Molecular Probes) to evaluate calcium fluxes after stimulation. Levels of free intracellular calcium were measured in CD20+ B cells with the use of flow cytometry in a FACSVantage station (BD Biosciences) before and after stimulation with Staphylococcus aureus Cowan I (Calbiochem) in a 1:500 dilution or with 20 μg of goat antihuman IgM F(ab') 2 per milliliter (Jackson Immunoresearch Laboratories). Subsequently, 2 μg of ionomycin per milliliter (Molecular Probes) was added to control for intracellular loading of indo-1.
B-Cell Proliferation
Enriched blood B cells (1×10 5 per well) were cultured in 96-well flat-bottomed plates for 48 or 72 hours at 37°C and stimulated with S. aureus Cowan I in a 1:10,000 dilution or with 20 μg of anti-IgM F(ab') 2 per milliliter. Proliferation of the B cells was assessed by incorporating 0.5 μCi of [ 3 H]thymidine in each well.
In Vivo Vaccination with Rabies Vaccine
Patients, relatives, and controls were vaccinated twice with the human diploid-cell rabies vaccine (Institut Pasteur Merieux, Merck Sharp & Dohme) according to standard protocols. Antibody levels and avidity were measured as previously described. 26
R esults

Identification of CD19 Defects
Flow-cytometric immunophenotyping with antibodies against the cell-surface markers CD3 (on T cells), CD16 or CD56 or both (on natural killer cells), and CD19 or CD20 (on B cells) results in the identification of more than 95 percent of lymphocytes. All four patients had normal absolute numbers of CD20+ B cells. In contrast, membrane expression of CD19 on B cells was not detectable in Patient 1 and was barely detectable in Patients 2, 3, and 4 ( Fig. 1A) .
Sequencing of the CD19 gene in Patient 1 revealed an insertion of an adenine in exon 6 of both alleles of CD19. This insertion causes a frame shift, both the x axis and y axis show a log (base-10) scale. Patient 1 showed a complete lack of CD19 on CD20+ blood B cells, and the three other patients had variable traces. Three CD19 monoclonal antibodies (SJ25C1, 4G7, and HIB19) and one CD20 monoclonal antibody (L27) were used. PerCP denotes perdinin chlorophyll protein, APC allophycocyanin, PE phycoerythrin, and FITC fluorescein isothiocyanate. Control B cells stained positive for both CD19 and CD20. Panel B shows the location of mutations in the CD19 gene. Exons 1 through 14 code for CD19, which consists of two immunoglobulin-like domains (Ig1 and Ig2), a transmembrane domain (TM), and many cytoplasmic domains containing nine conserved tyrosines. Patient 1 had a homozygous insertion of an adenine in exon 6, resulting in three altered amino acids and a premature stop codon at position 328 of the protein. Patients 2, 3, and 4 had a homozygous dinucleotide deletion in exon 11, resulting in two altered amino acids and a premature stop codon at position 465. The premature stop codons lead to the deletion of part of the cytoplasmic domains, including the two tyrosine residues that are critical for signal transduction through CD19 (indicated with a large y in the diagram of the protein). 25 Panels C and D show the pedigrees of Patient 1 and Patients 2, 3, and 4, respectively. Half-solid symbols denote known carriers of the mutation, solid symbols family members who are homozygous for the mutation, symbols with a slash deceased members, squares male family members, circles female family members, and N family members who are known not to be carriers. and thus there is a premature stop codon at the intracellular amino acid 328 (Fig. 1B) . Patients 2, 3, and 4 were homozygous for a dinucleotide deletion of guanine and adenine in exon 11, resulting in a premature stop codon at the intracellular amino acid 465 (Fig. 1B) . Living parents and several members of both families carried one mutated allele (Fig. 1C and 1D ) but had no clinical features of immunodeficiency.
Normal levels of CD19 transcripts were found in B cells from all patients (data not shown). Western blotting did not detect the CD19 protein in B cells from Patient 1, because the CD19 in this patient lacked most of the cytoplasmic domains. However, a reduction in intracellular levels of CD19 was observed in B cells from Patient 4 (data not shown), confirming the flow-cytometric results.
Membrane Expression of the CD19 Complex
The level of expression of CD19 in the carriers of the mutations was lower than that in controls ( Fig. 2A ). In addition, CD21 expression on the surface of patients' B cells was also reduced (Fig. 2B ). CD81 and CD225 molecules were expressed at normal levels by the B cells of all patients and carriers (data not shown).
B-Cell Differentiation
The precursor B-cell compartment in the bone marrow of Patient 1 showed a normal relative distribution of all differentiation stages (data not shown). 23 Ig-κ+ B cells and Ig-λ+ B cells were present in normal ratios in blood samples from all patients. Moreover, B cells from all four patients had normal expression of other membrane-bound molecules, including IgM, IgD, CD20, CD22, CD38, CD40, beta 2 -microglobulin, and HLA-DR. However, all four patients had decreased levels of CD5+ B cells (8 to 12 percent) and CD27+ memory B cells (1 to 6 percent) in blood, as compared with levels in age-matched controls and carriers (19 to 41 percent for CD5+ and 17 to 28 percent for CD27+) (Fig.  2C and 2D ). Memory B cells that switched immunoglobulin class were CD27+IgD−, lacking IgM and IgD, and were present in decreased numbers in blood samples from all patients. Sequencing of the V H -C α and V H -C γ transcripts showed somatic hypermutations in a pattern suggesting the potential to produce an antigen-selected B-cell-receptor repertoire, which is a molecular sign of a response to antigenic stimulation (data not shown).
The numbers of CD27+ memory B cells in carriers in the family of Patient 1 were similar to those in controls, whereas carriers in the family of Patients 2, 3, and 4 had fewer memory B cells than controls (Fig. 2D ). In general, however, in contrast to the patients, the carriers in the family of Patients 2, 3, and 4 had mainly memory B cells that had switched immunoglobulin class and normal serum immunoglobulin levels (data not shown).
Germinal Centers in Secondary Lymphoid Organs
Histologic analysis of a sample of cervical lymph node from Patient 1 showed multiple B-cell follicles of small-to-moderate size with proliferation centers on immunohistochemical staining for CD79a, BCL-2, BCL-6, CD21, and Ki67 (Fig. 3A) . Follicles of normal size and architecture were also found in the tonsil specimen from Patient 2 (Fig. 3B) .
Calcium Mobilization and Proliferation on Stimulation of the B-cell Receptor
B-cell receptor-mediated activation causes an initial flux of calcium from the rough endoplasmic reticulum into the cytoplasm, followed by a sustained influx of extracellular calcium. 27 As compared with control B cells, the B cells from all four patients with CD19 deficiency exhibited defective calcium fluxes after stimulation with an anti-IgM antibody, which cross-links IgM molecules on the B-cell surface. No calcium influx or efflux was observed in the B cells from Patient 1, whereas the initial calcium influx was delayed in B cells from Patients 2, 3, and 4. Furthermore, calcium efflux in all four patients was delayed and remained low for the duration of the experiment (Fig. 4A; data stimulation with S. aureus Cowan I or an anti-IgM antibody, as compared with B cells from the control (Fig. 4B) . B cells from the parents of Patient 1, who are carriers of the mutation, showed intermediate proliferation in response to both S. aureus Cowan I and anti-IgM antibody (Fig. 4B) . B cells from carriers in the family of Patients 2, 3, and 4 proliferated normally after stimulation with S. aureus Cowan I or anti-IgM antibody (not shown).
Antibody Response to Rabies Vaccine
To test the primary and secondary antibody responses in vivo, all patients were vaccinated twice with rabies vaccine (at week 0 and week 13). The primary response of production of IgG antirabies antibody in Patient 1 was low but detectable, whereas Patients 2, 3, and 4 did produce IgG anti-rabies antibodies after the first vaccination. The secondary IgG response, after week 13, in all patients was below the 95 percent confidence interval of the normal response (Fig. 4C) . 26 Furthermore, no increase in avidity was observed in Patient 2, 3, or 4, and Patient 1 had only a marginal increase in avidity during the secondary response (Fig. 4D) . The second antibody response and the increase in avidity maturation were normal in the two carriers evaluated in the family of Patients 2, 3, and 4 ( Figs. 4C and 4D) . 
Figure 4 (facing page). In Vitro Responses of B Cells and Antibody Responses to Rabies Vaccine.
The stimulation of blood mononuclear cells with anti-IgM antibody did not result in an initial calcium influx in CD20+ B cells from Patient 1 and resulted in a delayed initial calcium influx in cells from Patient 4, as compared with the control cells (Panel A; the dashed line indicates the peak of the initial calcium influx in the control). In Patient 4, the subsequent calcium flux was sustained and relatively high. No defect in calcium flux was seen in carriers of the CD19 mutation (not shown). Ionomycin was added as a control for intracellular loading of indo-1. The proliferation of B cells from Patient 1 was less than that in two carriers and a control from her family after stimulation with Staphylococcus aureus Cowan I (SAC) or anti-IgM antibody (Panel B). The blood B cells were harvested and cultured for 48 or 72 hours in medium alone or medium with either SAC or anti-IgM antibody. The proliferation index is the ratio of the counts per minute of stimulated and unstimulated B cells. Each experiment was performed in triplicate, and T bars represent standard errors. The levels of anti-rabies IgG antibodies were subnormal in the four patients after an initial vaccination at week 0 (arrow) and a booster vaccination at week 13 (arrowhead) (Panel C). The relative avidity index of the antibody was also low in these patients (Panel D). These patients were compared with 18 controls vaccinated according to the same methods 26 ; the gray area represents the 95 percent confidence interval of the anti-rabies IgG level and avidity index. Two carriers from the family of Patients 2, 3, and 4 were also tested and had a normal quantitative and qualitative response. NaSCN denotes sodium thiocyanate. 
Discussion
We described four patients (from two different families) with homozygous mutations in CD19 and showed that their profound hypogammaglobulinemia resulted from a poor response to antigen by mature B cells. Both CD19 mutations were frameshift mutations, causing premature stop codons that result in the deletion of the total cytoplasmic domain (in the family of Patient 1) or a major part of the cytoplasmic domain (in family B). Both truncations result in the lack of the three C-terminal tyrosine residues, two of which have been shown to be critical for signal transduction through CD19 (Fig. 1B) . 25 These mutations are not likely to be polymorphisms; CD19 is the most broadly used B-cell marker for flow-cytometric immunophenotyping of lymphocytes and has not been found to be lacking in large-scale studies of healthy children. 16, 28 Moreover, the B cells of heterozygous carriers of the mutation expressed CD19, albeit at slightly lower levels than noncarriers. Futhermore, CD19 -together with CD21, CD81, and CD225forms a signaling complex that decreases the threshold for the activation of B cells as mediated by the B-cell receptor. 29 B cells from CD81-knockout mice have decreased CD19 expression. 30, 31 The mature B cells from our patients, however, had a normal level of expression of CD81 and CD225 but a reduced level of expression of CD21, suggesting a dependency of CD21 on CD19. Normal levels of CD19 transcripts in the B cells of these patients indicate that the reduction in the level of the protein does not result from nonsense-mediated decay of mRNA, but rather from the instability of the truncated CD19 proteins. This interpretation is consistent with the observation that truncated (but otherwise stable) CD19 molecules can associate with CD81 and CD225 on the membranes of B cells in which 95 percent of the cytoplasmic domains of CD19 are deleted. 32 The CD19 deficiency did not disturb the differentiation of precursor B cells in the bone marrow. Still, CD19-deficient B cells may undergo differentiation less efficiently than CD19+ B cells, as has been observed in CD19-knockout mice. 33, 34 Nevertheless, our patients had normal numbers of mature B cells in blood.
The numbers of CD5+ B cells in our patients were decreased, as they are in CD19-knockout mice. 35, 36 CD5 is a negative regulator of B-cell receptor signaling, and in mice, this marker defines the subgroup of autoreactive B-1a cells. 37, 38 It is likely that, in our patients, the inhibitory effect of CD5 on B-cell-receptor signaling is superfluous in the absence of CD19.
The numbers of CD27+IgD+ and CD27+IgD− memory B cells in blood from all four patients were decreased. Together with the finding of decreased serum immunoglobulin levels, this finding suggests that terminal differentiation of B cells into memory B cells and plasma cells is affected. In two patients, secondary lymphoid tissues contained follicles of small-to-moderate size with germinal centers that appeared normal. CD19knockout mice lack germinal centers, but centers appear when the animals are challenged with live virus. 39 IgG antibodies and circulating memory B cells are defective in these mice, 39 as they are in our four patients.
IgG and IgA transcripts with antigen-driven hypermutation were found in our patients at variable levels, indicating that CD19-deficient B cells are in principle able to undergo antigen-dependent differentiation, albeit with reduced efficiency. In mice, defects in CD19 signaling due to mutations in critical intracellular tyrosines result in the absence of high-affinity antibodies owing to low B-cell proliferation and abnormal immunoglobulin-class switching. 25, 40, 41 The inefficient response of CD19-deficient B cells in these patients probably results from the loss of dual antigen recognition through the B-cell receptor and the CD19 complex. 15, 42 The B cells from all four patients had abnormal calcium fluxes on stimulation, but the differences between Patient 1 and the other three patients may be due to the presence of different mutations. Patient 1 lacked all the intracellular domains responsible for signal transduction 32 ; in Patients 2, 3, and 4, the CD19 molecule lacked only 92 amino acids at the intracellular C-terminal end, which contains two critical tyrosines that are required for most functions of CD19. 25 Most of the intracellular domains were present, potentially permitting some B-cell signaling. 43 Nevertheless, all four patients with CD19 deficiency had substantially decreased antibody responses (levels and avidity) after vaccination with rabies vaccine. We conclude that the CD19 signals that normally enable B-cell responses to antigenic stimuli are lacking in our patients.
This study shows that the disruption of CD19 signaling results in a primary antibody deficiency, mainly characterized by a poor antigen-specific response. On the basis of the crucial role of CD19 in signaling by the B-cell receptor on antigen recognition, it is likely that defects in other members of the CD19 complex (CD21, CD81, and CD225) also lead to antibody deficiency in humans.
